Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!
About this episode
The episode features discussions on SGLT2 inhibitors, diabetes medications, and the ADA's statement on employment and diabetes.
With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE , the official podcast of Diabetes, Obesity, and CardioMetabolic CARE . Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 1:15 Our hosts speak with Katherine R. Tuttle , MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001 . 8:50 Next, Richard introduces Alexander Turchin , MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate…
People in this episode
Hosts: Richard Beaser, Jane Reusch
Guests: Katherine R. Tuttle, Alexander Turchin
Topics covered
- SGLT2 inhibitors
- chronic kidney disease
- type 2 diabetes
- cardiovascular risk
- diabetes medications
- employment and diabetes
Keywords
- SGLT2
- CKD
- T2D
- CVD risk
- diabetes medications
- employment
- ADA
Mentioned in this episode
Organizations: American Diabetes Association, Diabetes, Obesity, and CardioMetabolic CARE
Books & works: SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis, Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022
More episodes of DOC Updates
- Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone
- Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance
- Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D
- Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!
- Special Edition: Hypertension Part I—Overview and Management
Explore listener stats, chart rankings, contacts and more on the DOC Updates podcast page.